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Abstract
Background: The outcome of patients with upper extremity deep vein thrombosis (UEDVT) has not been consistently com-
pared with that in patients with lower extremity deep vein thrombosis (LEDVT). Methods: We used the Registro Informatizado
de Enfermedad Trombo Embólica (RIETE) registry to compare the outcomes during the course of anticoagulant therapy in
patients with UEDVT versus outcomes in patients with LEDVT. Results: As of August 2015, 37,366 patients with acute DVT had
been enrolled in RIETE: 35094 (94%) had LEDVT, 1334 (3.6%) non-catheter related UEDVT (672 unprovoked and 662 provoked)
and 938 (2.5%) had catheter-related UEDVT. During the course of anticoagulation, patients with unprovoked UEDVT had a
higher rate of DVT recurrences (hazard ratio [HR]: 2.22; 95% CI: 1.37-3.43) and a similar rate of PE recurrences or major bleeding
than those with unprovoked LEDVT. Patients with non-catheter-related provoked UEDVT had a similar outcome than those with
provoked LEDVT. Among patients with UEDVT, those with non-catheter related unprovoked UEDVT had a lower rate of PE
recurrences (HR: 0.06; 95% CI: 0-0.35) and major bleeding (HR: 0.20; 95% CI: 0.08-0.46) than those with catheter-related UEDVT
or those with non-catheter related provoked UEDVT (HR: 0.10; 95% CI: 0.004-0.60; and 0.22; 95% CI: 0.08-0.52, respectively).
On multivariable analysis, any difference had disappeared. Conclusion: During the course of anticoagulation, patients with
UEDVT had a similar outcome than those with LEDVT. Among UEDVT patients, there were some differences according to the
presence of catheter or additional risk factors for DVT. These differences disappeared after adjusting for potentially confounding
variables.
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Venous thromboembolism (VTE) represents a major cause of
morbidity and mortality in the United States.1 The Joint Commis-
sion and National Quality Forum monitors VTEs as one of its core
performance measures, specifically VTE prophylaxis.2 The
occurrence of lower extremity deep vein thrombosis (LEDVT),
averaging approximately 187 000 cases per year in the United
States, is considered the third most frequent vascular disease after
myocardial infarction and stroke.3,4 Patients with acute LEDVT
may have risk factors such as surgery, prolonged length of pro-
cedures, weakness or paresis, malignancy, and advanced age.
Additionally, upper extremity deep vein thrombosis (UEDVT)
is diagnosed in approximately 4% to 10% of all cases with deep
vein thrombosis (DVT) and is categorized into noncatheter-
related and catheter-related UEDVT.5-15 Noncatheter-related
UEDVT may be idiopathic or associated with cancer, estrogen
use, or other risk factors. Catheter-related UEDVT may be sec-
ondary to a catheter, a pacemaker, or a port system. Few studies
have compared the natural history of patients with UEDVT (in
terms of symptomatic VTE recurrences or major bleeding) during
the course of anticoagulant therapy with those with LEDVT.
Registro Informatizado de Enfermedad TromboEmbólica
(RIETE or in English: Computerized Registry of Patients with
Venous Thromboembolism) is a multicenter, ongoing, interna-
tional (Spain, Belgium, Czech Republic, France, Greece, Israel,
Italy, Latvia, Republic of Macedonia, Switzerland, United States,
Canada, Ecuador, and Venezuela) observational registry of con-
secutive patients with symptomatic, objectively confirmed, acute
VTE.16-20 Since its inception in 2001, the design of the RIETE is
to record data including the clinical characteristics, treatment
patterns, and outcomes in patients diagnosed with VTE. Using
the RIETE cohort, the present study compared the clinical char-
acteristics, treatments, and outcome during the course of antic-
oagulation of patients with UEDVT versus those with LEDVT.
Patients and Methods
Inclusion Criteria
Consecutive patients with symptomatic, acute DVT or pulmon-
ary embolism (PE) confirmed by objective tests (compression
ultrasonography or contrast venography for DVT; helical com-
puted tomography [CT] scan, ventilation–perfusion lung scinti-
graphy, or angiography for PE) were enrolled in RIETE. Patients
were excluded if they were currently participating in a therapeu-
tic clinical trial with a blinded therapy. All patients (or their legal
power of attorney) provided written or oral consent for partici-
pation in the registry, in accordance with local ethics committee
requirements. This analysis was approved by the ethics commit-
tee of the Hospital Universitari Germans Trias i Pujol (Bada-
lona, Spain) and by the institutional review board of NorthShore
University Health System (Evanston, Illinois).
Physicians participating in the RIETE registry made all
efforts to enroll consecutive patients. Data were recorded onto
a computer-based case report form at each participating hospital
and submitted to a centralized coordinating center through a
secure website. To ensure the validity of the information entered
into the database, one of the specially trained monitors visited
each participating hospital and compared information in 25 to 50
randomly chosen patient records with the information entered
into the RIETE database. For data quality assessment, monitors
assessed 4100 random records from all participating hospitals
that included 1 230 000 measurements. These data showed a
95% overall agreement between the registered information and
the patient records. The RIETE also used electronic data mon-
itoring to detect inconsistencies or errors and attempted to
resolve any discrepancies by contacting the local coordinators.
Study Design
We conducted a retrospective cohort study that used prospec-
tively collected data from patients enrolled in the RIETE regis-
try. All patients diagnosed with upper or lower DVT in RIETE
were evaluated. Patients with UEDVT were then categorized by
noncatheter-related unprovoked DVT, noncatheter-related pro-
voked DVT, and catheter-related UEDVT. The major outcome
was the rate of symptomatic VTE recurrences and major bleed-
ing events appearing during the course of anticoagulant therapy.
Bleeding events were classified as ‘‘major’’ if they were overt
and required a transfusion of 2 U or more of blood, or were
retroperitoneal, spinal, or intracranial, or when they were fatal.
Fatal PE, in the absence of autopsy, was defined as any death
appearing within the first 10 days after PE diagnosis, in the
absence of any alternative cause of death. Fatal bleeding was
defined as any death occurring within 10 days of a major bleed-
ing episode, in the absence of an alternative cause of death.
Deep vein thrombosis was considered to be unprovoked in the
absence of recent immobility, surgery, bone fracture, active can-
cer, estrogen use, pregnancy, puerperium, or long-term travel.
Immobilized patients were defined as nonsurgical patients who
had been immobilized (ie, total bed rest with bathroom privileges)
for4 days in the 2-month period prior to VTE. Surgical patients
were defined as those who underwent a surgical intervention in
the 2 months prior to VTE. Recent bleeding was defined as a
major bleeding episode <30 days prior to VTE. Active cancer
was defined as newly diagnosed cancer, metastatic cancer, or
cancer that was being treated (ie, surgery, chemotherapy, radio-
therapy, support therapy, or combined treatments).
Treatment and Follow-Up
Patients were managed according to the clinical practice of
each participating hospital (ie, there was no standardization of
treatment). Patients were followed up in the outpatient clinic
or physician’s office. During each visit, any signs or symp-
toms suggesting VTE recurrences or bleeding complications
were noted. Each episode of clinically suspected recurrent
DVT or PE was investigated by repeat compression ultra-
sound, lung scanning, helical CT scan, or pulmonary angio-
graphy as appropriate. Most outcomes were classified as
reported by the clinical centers. However, if staff at the coor-
dinating center were uncertain how to classify a reported
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outcome, that event was reviewed by a central adjudicating
committee (<10% of events).
Statistical Analysis
Categorical variables were compared using w2 test (2-sided)
and Fisher exact test (2-sided). Odds ratios (ORs) and corre-
sponding 95% confidence intervals (CIs) were calculated, and
a P value <.05 was considered to be statistically significant.
The association between the type of DVT and outcome was
assessed using the Cox proportional hazards regression
model, estimated by a forward step method. All variables
achieving a significance level of .1 on univariable analysis
were considered for inclusion in the logistic regression model.
Statistical analyses were conducted with SPSS for Windows
Release 17.0 (SPSS, Inc, Chicago, Illinois, USA).
Role of the Funding Source
The funders of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of the
report. The corresponding author had full access to all the data
in the study and had final responsibility for the decision to
submit for publication.
Results
As of August 2015, 37 366 patients with acute DVT had been
enrolled in RIETE. Of these, 35 094 (94%) had LEDVT, 1334
(3.6%) had noncatheter-related UEDVT, and 938 (2.5%) had
catheter-related UEDVT. Among patients with noncatheter-
related UEDVT, 672 (50%) had unprovoked and 662 had pro-
voked UEDVT.
Table 1. Clinical Characteristics, Treatment, and Outcome in Patients With Unprovoked UEDVT Versus in Those With Unprovoked LEDVT.
Noncatheter-related,
Unprovoked UEDVT Unprovoked LEDVT
Odds Ratio
(95% CI)
Patients, N 672 15 856
Clinical characteristics
Male gender 407 (61%) 9241 (58%) 1.10 (0.94-1.29)
Mean age + SD, years 47 + 20 66 + 16 P < .001
Underlying conditions
Chronic lung disease 35 (5.2%) 1578 (10%) 0.50 (0.35-0.70)
Chronic heart failure 28 (4.2%) 723 (4.6%) 0.91 (0.62 -1.34)
CrCl levels <60 mL/min 101 (15%) 5251 (33%) 0.36 (0.29-0.44)
Anemia 114 (17%) 3334 (21%) 0.77 (0.63-0.94)
Recent major bleeding 5 (0.74%) 94 (0.59%) 1.26 (0.51-3.10)
Prior VTE 96 (14%) 3557 (22%) 0.58 (0.46-0.72)
Symptomatic PE at baseline
Yes 73 (11%) 3927 (25%) 0.37 (0.29-0.47)
Initial therapy
Low-molecular-weight heparin 571 (85%) 14 421 (91%) 0.56 (0.45-0.70)
Mean LMWH doses (IU/kg/d) 177 + 39 176 + 39 P ¼ .341
Unfractionated heparin 38 (5.7%) 699 (4.4%) 1.30 (0.93 -1.82)
Thrombolytics 18 (2.7%) 107 (0.67%) 4.05 (2.44-6.72)
Long-term therapy
Vitamin K antagonists 495 (74%) 12 804 (81%) 0.67 (0.56-0.79)
Low-molecular-weight heparin 144 (21%) 2288 (14%) 1.62 (1.34-1.95)
Mean LMWH doses (IU/kg/d) 154 + 44 145 + 47 P <0.001
Duration (mean days + SD) 230 + 263 297 + 370 <.001
Median (IQR) 174 (109-239) 191 (116-329) <.001







Recurrent DVT 20 4.90 (3.08-7.44) 279 2.21 (1.96-2.48) 2.22 (1.37-3.43)
Recurrent PE 1 0.24 (0.01-1.17) 110 0.86 (0.71-1.03) 0.28 (0.01-1.39)
Major bleeding 6 1.43 (0.58-2.98) 264 2.06 (1.83-2.32) 0.69 (0.28-1.46)
Death 10 2.37 (1.20-4.22) 329 2.55 (2.29-2.84) 0.93 (0.47-1.67)
Fatal PE 1 0.24 (0.01-1.17) 30 0.23 (0.16-0.33) 1.02 (0.05-5.34)
Fatal initial PE 0 – 23 0.18 (0.12-0.26) –
Fatal recurrent PE 1 0.24 (0.01-1.17) 7 0.05 (0.02-0.11) 4.36 (0.19-28.2)
Fatal bleeding 0 – 29 0.22 (0.15-0.32) –
Abbreviations: CrCl, creatinine clearance; DVT, deep vein thrombosis; IQR, interquartile range; IU, international units; LEDVT, lower extremity deep vein
thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; SD, standard deviation; UEDVT, upper extremity deep vein thrombosis.
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Unprovoked UEDVT Versus Unprovoked LEDVT
Patients with unprovoked UEDVT were 19 years younger
than those with unprovoked LEDVT and less likely to have
chronic lung disease, anemia, renal insufficiency, or prior
VTE (Table 1). At baseline, they less likely presented with
symptomatic PE concomitantly (OR: 0.37; 95% CI: 0.29-
0.47). Most patients in both subgroups (85% and 91%, respec-
tively) received initial therapy with low-molecular-weight
heparin (LMWH), at similar doses. Then, most (74%
and 81%) switched to vitamin K antagonists (VKAs) for
long-term therapy. During the course of anticoagulant ther-
apy, patients with unprovoked UEDVT had a higher rate of
DVT recurrences than those with unprovoked LEDVT
(hazard ratio [HR]: 2.22; 95% CI: 1.37-3.43) and a similar
rate of PE recurrences or major bleeding.
Noncatheter-Related, Provoked UEDVT
Versus Provoked LEDVT
Compared with patients with provoked LEDVT, those with
noncatheter-related provoked UEDVT were 8 years younger and
Table 2. Clinical Characteristics, Treatment, and Outcome in Patients With Noncatheter-Related, Provoked UEDVT Versus Those With
Provoked LEDVT.
Noncatheter-Related,
Provoked UEDVT Provoked LEDVT Odds Ratio (95% CI)
Patients, N 662 19 238
Clinical characteristics
Male gender 295 (45%) 8731 (45%) 0.97 (0.83-1.13)
Mean age + SD, years 56 + 19 64 + 19 P < .001
Underlying conditions
Chronic lung disease 56 (8.5%) 1855 (9.6%) 0.87 (0.66-1.14)
Chronic heart failure 32 (4.8%) 1115 (5.8%) 0.83 (0.58-1.18)
CrCl levels <60 mL/min 152 (23%) 7110 (37%) 0.51 (0.42-0.61)
Anemia 310 (47%) 8509 (44%) 1.11 (0.95-1.30)
Recent major bleeding 16 (2.4%) 604 (3.1%) 0.76 (0.46-1.26)
Prior VTE 74 (11%) 2376 (12%) 0.89 (0.70-1.14)
Risk factors for DVT
Recent surgery 89 (13%) 3551 (18%) 0.69 (0.55-0.86)
Immobility 4 days 123 (19%) 8219 (43%) 0.31 (0.25-0.37)
Active cancer 334 (50%) 5803 (30%) 2.36 (2.02-2.75)
Estrogen use 132 (20%) 1865 (9.7%) 2.32 (1.91-2.82)
Pregnancy/puerperium 20 (3.0%) 544 (2.8%) 1.07 (0.68-1.68)
Symptomatic PE at baseline
Yes 87 (13%) 4674 (24%) 0.47 (0.38-0.59)
Initial therapy
LMWH 586 (89%) 17 494 (91%) 0.77 (0.60-0.98)
Mean LMWH doses (IU/kg/d) 17 2+ 45 175 + 43 P ¼ .341
Unfractionated heparin 30 (4.5%) 928 (4.8%) 0.94 (0.65-1.36)
Thrombolytics 7 (1.1%) 112 (0.58%) 1.83 (0.85-3.93)
Long-term therapy
Vitamin K antagonists 251 (38%) 10 601 (55%) 0.50 (0.42-0.58)
LMWH 361 (55%) 7309 (38%) 1.96 (1.68-2.29)
Mean LMWH doses (IU/kg/d) 155 + 47 147 + 47 P < .001
Duration (mean days + SD) 178 + 190 221 + 293 <.001
Median (IQR) 122 (91-215) 149 (95-231) <.001




100 Patient-Years Hazard Ratio (95% CI)
Recurrent DVT 9 2.81 (1.37-5.16) 373 3.29 (2.97-3.64) 0.85 (0.41-1.58)
Recurrent PE 8 2.50 (1.16-4.74) 252 2.19 (1.93-2.47) 1.14 (0.53-2.20)
Major bleeding 21 6.59 (4.19-9.90) 614 5.34 (4.93-5.77) 1.23 (0.78-1.87)
Death 114 35.3 (29.3-42.3) 2,557 22.0 (21.2-22.9) 1.61 (1.33-1.93)
Fatal PE 6 1.86 (0.75-3.87) 148 1.27 (1.08-1.49) 1.46 (0.58-3.10)
Fatal initial PE 3 0.93 (0.24-2.53) 81 0.70 (0.56-0.86) 1.33 (0.33-3.74)
Fatal recurrent PE 3 0.93 (0.24-2.53) 67 0.58 (0.45-0.73) 1.61 (0.40-4.55)
Fatal bleeding 6 1.86 (0.75-3.87) 136 1.17 (0.99-1.38) 1.59 (0.63-3.38)
Abbreviations: CrCl, creatinine clearance; IQR, interquartile range; IU, international units; LEDVT, lower extremity deep vein thrombosis; LMWH,
low-molecular-weight heparin; PE, pulmonary embolism; SD, standard deviation; UEDVT, upper extremity deep vein thrombosis.
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less likely to have renal insufficiency, recent surgery, or recent
immobility but more likely to have active cancer or use of estro-
gens (Table 2). At baseline, patients with noncatheter-related
provoked UEDVT less likely presented with symptomatic PE
than those with provoked LEDVT (HR: 0.47; 95% CI: 0.38-
0.59). Most patients in both subgroups (89% and 91%,
respectively) treated with LMWH, but only 38% of patients with
UEDVT and 55% of those with LEDVT switched to VKA for
long-term therapy. During the course of anticoagulant therapy,
patients with noncatheter-related provoked UEDVT had a sim-
ilar rate of PE recurrences, DVT recurrences, or major bleeding
than those with provoked LEDVT.







Patients, N 938 672 662
Clinical characteristics
Male gender 514 (55%) 407 (61%)b 295 (45%)c
Mean age + SD, years 59 + 16 47 + 20c 56 + 19c
Underlying conditions
Chronic lung disease 86 (9.2%) 35 (5.2%)d 56 (8.5%)
Chronic heart failure 69 (7.4%) 28 (4.2%)d 32 (4.8%)b
CrCl levels <60 mL/min 255 (27%) 101 (15%)c 152 (23%)
Anemia 611 (65%) 114 (17%)c 310 (47%)c
Recent major bleeding 43 (4.6%) 5 (0.74%)c 16 (2.4%)b
Prior VTE 67 (7.1%) 96 (14%)c 74 (11%)d
Risk factors for DVT
Recent surgery 215 (23%) 0c 89 (13%)c
Immobility 4 days 149 (16%) 0c 123 (19%)
Active cancer 491 (52%) 0c 334 (50%)
Estrogen use 20 (2.1%) 0c 132 (20%)c
Pregnancy/puerperium 7 (0.75%) 0b 20 (3.0%)c
Symptomatic PE at baseline
Yes 58 (6.2%) 73 (11%)c 87 (13%)c
Initial therapy
LMWH 858 (91%) 571 (85%)c 586 (89%)
Mean LMWH doses (IU/kg/d) 166 + 46 177 + 39 172 + 45c
Unfractionated heparin 51 (5.4%) 38 (5.7%) 30 (4.5%)
Thrombolytics 7 (0.75%) 18 (2.7%)d 7 (1.1%)
Long-term therapy
Vitamin K antagonists 290 (31%) 495 (74%)c 251 (38%)d
LMWH 602 (64%) 144 (21%)c 361 (55%)c
Mean LMWH doses (IU/kg/d) 148 + 47 154 + 44c 155 + 47
Duration (mean days + SD) 166 + 202 230 + 263c 178 + 190
Median (IQR) 109 (91-182) 174 (109-239) 122 (91-215)







Recurrent DVT 14 3.36 (1.91-5.50) 20 4.90 (3.08-7.44) 9 2.81 (1.37-5.16)
Recurrent PE 16 3.82 (2.26-6.06) 1 0.24 (0.01-1.17)c 8 2.50 (1.16-4.74)
Major bleeding 30 7.14 (4.91-10.1) 6 1.43 (0.58-2.98)c 21 6.59 (4.19-9.90)
Death 104 24.5 (20.1-29.5) 10 2.37 (1.20-4.22)c 114 35.3 (29.3-42.3)d
Fatal PE 5 1.18 (0.43-2.61) 1 0.24 (0.01-1.17) 6 1.86 (0.75-3.87)
Fatal initial PE 1 0.24 (0.01-1.16) 0 – 3 0.93 (0.24-2.53)
Fatal recurrent PE 4 0.94 (0.30-2.27) 1 0.24 (0.01-1.17) 3 0.93 (0.24-2.53)
Fatal bleeding 8 1.88 (0.87-3.58) 0 – 6 1.86 (0.75-3.87)
Abbreviations: CrCl, creatinine clearance; DVT, deep vein thrombosis; IQR, interquartile range; IU, international units; LMWH, low-molecular-weight heparin;
PE, pulmonary embolism; SD, standard deviation; UEDVT, upper extremity deep vein thrombosis; VTE, venous thromboembolism.
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Differences Between Patients With UEDVT
Patients with catheter-related UEDVT (central line 386, periph-
eral line 93, port system 243, pacemaker 91, other 10) were sig-
nificantly older than those with unprovoked UEDVT and younger
than those with noncatheter-related, provoked UEDVT (Table 3).
They were most likely to have underlying diseases such as chronic
lung disease or heart failure, renal insufficiency, anemia, or recent
major bleeding than those with noncatheter-related UEDVT. At
baseline, patients with catheter-related UEDVT were less likely
to present with concomitant PE than the other 2 subgroups (Table
3). During the course of anticoagulant therapy, patients with
noncatheter-related unprovoked UEDVT had a lower rate of PE
recurrences (HR: 0.06; 95% CI: 0-0.35) and major bleeding (HR:
0.20; 95% CI: 0.08-0.46) than those with catheter-related
UEDVT or those with noncatheter-related provoked UEDVT
(HR: 0.10, 95% CI: 0.004-0.60 and 0.22, 95% CI: 0.08-0.52,
respectively). On multivariable analysis, any difference in out-
come between subgroups had disappeared and could be explained
by differences in the proportion of patients with cancer, conco-
mitant diseases, or risk factors.
Discussion
Traditionally, patients with UEDVT have been considered at
low risk to develop PE. However, no studies have consistently
compared the outcome during the course of anticoagulation in
patients with UEDVT versus LEDVT. Our data, obtained from
a large series of consecutive patients with acute DVT, confirm
that patients with UEDVT less likely presented with PE at
baseline than those with LEDVT (9.8% vs 25%, respectively),
as already reported. Interestingly, however, the rate of PE
recurrences appearing during the course of therapy in patients
with UEDVT was not inferior to the rate in those with LEDVT.
In fact, among patients with catheter-related UEDVT, the rate
was higher, although according to the results of the multivari-
able analysis, it may not be attributed to the DVT itself but to
potentially confounding variables, particularly cancer. In our
series, 1 in every 3 patients with UEDVT developing PE recur-
rences (8 of 25, 32%) died of recurrent PE. Thus, its clinical
relevance should not be underestimated.
Current guidelines of anticoagulant therapy recommend the
same initial and long-term therapy for patients with LEDVT or
UEDVT.21,22 In our experience, patients with noncatheter-
related UEDVT were much younger than those with LEDVT,
less likely to have chronic lung disease or renal insufficiency,
and less often presented with PE at baseline. On the contrary,
over half (58%) of the patients with catheter-related UEDVT
had cancer, and 65% had anemia. We might have expected that
their outcome during therapy would have been different. If
proven, we might have suggested that they would probably
benefit from different anticoagulant strategies (in intensity or
duration). However, we failed to find any difference in out-
come after adjusting for potentially confounding variables.
Thus, our data confirm that there seem to be no reason for
treating patients with UEDVT differently.
There are several limitations to the present study. First, it
was a retrospective analysis of patients who were recruited
consecutively, thereby subject to possible selection bias. Sec-
ond, there was not a standardized type of anticoagulation treat-
ment in our cohort. Therefore, it is unknown as to which type
and dose of various treatments is the most efficacious in the
reduction or causation of events such as recurrent VTE or
bleeding. Third, patients in the RIETE database were selected
in several different countries. The variability of practices in
different countries could potentially affect the study’s out-
comes. For instance, the dosing and timing of pharmacologic
treatment can vary according to each individual country’s pat-
tern of practice, underlying disease process, and/or presence or
absence of a diagnosed malignancy. In addition, there may
have been variables that were unaccounted for in our multi-
variate analysis. Finally, a variety of practitioners entered data
into the registry, which may lend itself to potential inaccuracies
in the data being reported.
In summary, after comparing LEDVT patients to those with
UEDVT, we found a number of differences in clinical charac-
teristics, underlying diseases, initial presentation, and thera-
peutic strategies. However, their outcome during the course
of anticoagulant therapy was similar. We also found significant
differences in clinical characteristics between the 3 subgroups
of patients with UEDVT, but any difference in outcome had
disappeared on multivariable analysis. This study suggests that
practitioners may be able to treat those patients with UEDVT in
a similar manner to those with LEDVT. Further prospective
trials, however, are needed to clarify this notion.
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Lorente, A. Lorenzo, O. Madridano, P. J. Marchena, J. M. Mar-
tı́n-Antorán, M. Martı́n, F. Martı́n-Martos, M. Monreal, M. V.
Morales, F. J. Muñoz, D. Nauffal, J. A. Nieto, M. J. Núñez,
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